TRML Valuation

Tourmaline Bio Inc

Add to Watchlist

Advanced Chart

22.170

-0.4(-1.772%)1D

Overview
Forecast
Valuation
Earnings

TRML Relative Valuation

TRML's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRML is overvalued; if below, it's undervalued.

Historical Valuation

Tourmaline Bio Inc (TRML) is now in the Fair zone, suggesting that its current forward PS ratio of 76.69 is considered Fairly compared with the five-year average of -6.11. The fair price of Tourmaline Bio Inc (TRML) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：22.50

Fair

-5.55

Trailing

Forward

0.00

EV/EBITDA

Tourmaline Bio Inc. (TRML) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-3.04

EV/EBIT

Tourmaline Bio Inc. (TRML) has a current EV/EBIT of -3.04. The 5-year average EV/EBIT is -3.63. The thresholds are as follows: Strongly Undervalued below -10.39, Undervalued between -10.39 and -7.01, Fairly Valued between -0.25 and -7.01, Overvalued between -0.25 and 3.12, and Strongly Overvalued above 3.12. The current Forward EV/EBIT of -3.04 falls within the Historic Trend Line -Fairly Valued range.

86.97

Tourmaline Bio Inc. (TRML) has a current PS of 86.97. The 5-year average PS is 16.01. The thresholds are as follows: Strongly Undervalued below -41.73, Undervalued between -41.73 and -12.86, Fairly Valued between 44.88 and -12.86, Overvalued between 44.88 and 73.76, and Strongly Overvalued above 73.76. The current Forward PS of 86.97 falls within the Strongly Overvalued range.

-6.67

P/OCF

Tourmaline Bio Inc. (TRML) has a current P/OCF of -6.67. The 5-year average P/OCF is -5.81. The thresholds are as follows: Strongly Undervalued below -15.16, Undervalued between -15.16 and -10.48, Fairly Valued between -1.13 and -10.48, Overvalued between -1.13 and 3.55, and Strongly Overvalued above 3.55. The current Forward P/OCF of -6.67 falls within the Historic Trend Line -Fairly Valued range.

-5.47

P/FCF

Tourmaline Bio Inc. (TRML) has a current P/FCF of -5.47. The 5-year average P/FCF is -6.39. The thresholds are as follows: Strongly Undervalued below -11.88, Undervalued between -11.88 and -9.14, Fairly Valued between -3.65 and -9.14, Overvalued between -3.65 and -0.90, and Strongly Overvalued above -0.90. The current Forward P/FCF of -5.47 falls within the Historic Trend Line -Fairly Valued range.

Tourmaline Bio Inc (TRML) has a current Price-to-Book (P/B) ratio of 2.07. Compared to its 3-year average P/B ratio of 0.75 , the current P/B ratio is approximately 175.96% higher. Relative to its 5-year average P/B ratio of 0.75, the current P/B ratio is about 175.96% higher. Tourmaline Bio Inc (TRML) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -11.38%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.38% , the current FCF yield is about -100.00% lower.

2.07

P/B

Median3y

0.75

Median5y

0.75

0.00

FCF Yield

Median3y

-11.38

Median5y

-11.38

Competitors Valuation Multiple

The average P/S ratio for TRML's competitors is 33.59, providing a benchmark for relative valuation. Tourmaline Bio Inc Corp (TRML) exhibits a P/S ratio of 86.97, which is 158.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Relay Therapeutics Inc

Performance Decomposition

Market capitalization of TRML increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of TRML in the past 1 year is driven by Unknown.